5/13/2013

Eli Lilly & Co. said it would stop developing the experimental drug enzastaurin as a treatment for diffuse large B-cell lymphoma after obtaining unfavorable results from a late-stage trial. The drug failed to significantly improve disease-free survival against placebo in patients at high risk of relapse after chemotherapy.

Related Summaries